Psychiatry and Neurology, Neurology · Brooklyn, NY
NPI
1346354982
Since 2006
Specialty
Psychiatry and Neurology, Neurology
Code 2084N0400X
Group practices
2
Medicare group memberships
Hospitals
0
Hospital affiliations
408 Jay St, Suite 300
Brooklyn, NY, 11201
Phone (718) 522-3000
Groups this clinician bills Medicare through
Medicare paid, 2024
$1.0M
82,180 services
Medicare patients, 2024
786
Average age 75
Drug cost, 2024
$5.3M
13,967 prescriptions
Company payments, 2025
$4,829
From 35 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Michael Amoashiy was code J0585 (injection, onabotulinumtoxina, 1 unit), 71,702 times for 142 patients. In total Michael Amoashiy billed 82,180 services in 54 codes, and Medicare paid $1.0M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2022-07-12.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0585 Injection, onabotulinumtoxina, 1 unit | Office | 71,702 | 142 | $4.94 | $354K |
| 97110 PT Treatment | Office | 2,092 | 55 | $19.22 | $40K |
| 99213 Office E&M - Established | Office | 1,763 | 685 | $72.45 | $128K |
| 95886 Electrical Nerve Conductivity | Office | 1,289 | 414 | $78.82 | $102K |
| G0283 Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | Office | 534 | 41 | $7.21 | $3,852 |
| 93880 Duplex Scan - Extracranial Arteries | Office | 349 | 348 | $159.35 | $56K |
| 64615 Musculoskeletal | Office | 318 | 117 | $136.02 | $43K |
| 95816 Neurologic | Office | 233 | 218 | $332.63 | $78K |
| 99203 Office E&M - New | Office | 224 | 224 | $91.23 | $20K |
| 95913 Electrical Nerve Conductivity | Office | 217 | 217 | $233.06 | $51K |
| 92547 Vision, Hearing, and Speech Services | Office | 172 | 172 | $9.08 | $1,561 |
| 92540 Vision, Hearing, and Speech Services | Office | 172 | 172 | $84.95 | $15K |
| 92537 Test - Miscellaneous | Office | 167 | 167 | $32.21 | $5,378 |
| 92546 Vision, Hearing, and Speech Services | Office | 166 | 166 | $112.00 | $19K |
| 95910 Electrical Nerve Conductivity | Office | 125 | 125 | $143.67 | $18K |
By year: 2022 $934K for 73,054 services; 2023 $1.1M for 80,799 services; 2024 $1.0M for 82,180 services.
Medicare prescription drug claims, 2024
In 2024, the drug Michael Amoashiy prescribed most often to Medicare patients was Gabapentin, with 819 prescriptions and refills. In total Michael Amoashiy wrote 13,967 Medicare prescriptions that cost $5.3M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Gabapentin Generic | 819 | 913 | 192 | $5,315 |
| Escitalopram Oxalate Generic | 708 | 749 | 137 | $2,767 |
| Diclofenac Sodium Generic | 587 | 617 | 186 | $109K |
| Memantine Hcl Generic | 478 | 514 | 86 | $6,658 |
| Donepezil Hcl Generic | 452 | 520 | 75 | $2,915 |
| Primidone Generic | 414 | 457 | 63 | $3,795 |
| Lidocaine Generic | 406 | 477 | 121 | $41K |
| Quetiapine Fumarate Generic | 381 | 423 | 81 | $1,904 |
| Rivastigmine Generic | 371 | 407 | 63 | $38K |
| Meloxicam Generic | 338 | 356 | 117 | $656 |
| Trazodone Hcl Generic | 320 | 336 | 73 | $987 |
| Carbidopa-Levodopa Carbidopa/Levodopa | 287 | 321 | 49 | $5,693 |
| Levetiracetam Generic | 274 | 296 | 30 | $3,098 |
| Ubrelvy Ubrogepant | 264 | 270 | 41 | $427K |
| Diclofenac Epolamine Generic | 239 | 257 | 68 | $163K |
Brand drugs: - claims; generic drugs: 10,553 claims; opioid claims: 180.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Michael Amoashiy $4,829 ($4,829 in general payments such as food, travel and fees) from 35 companies. The largest payer was Abbvie Inc. with $772.
| Company | Payments | Amount |
|---|---|---|
| Abbvie Inc. ABBV | 32 | $772 |
| Eisai Inc. 4523.T | 21 | $437 |
| Vanda Pharmaceuticals Inc. VNDA | 15 | $266 |
| Otsuka America Pharmaceutical, Inc. 4578.T | 11 | $265 |
| Axsome Therapeutics, Inc. AXSM | 16 | $249 |
| Lundbeck LLC | 17 | $249 |
| Neurocrine BioSciences, Inc. NBIX | 8 | $239 |
| Pfizer Inc. PFE | 8 | $208 |
| Novartis Pharmaceuticals Corporation NVS | 18 | $198 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) JNJ | 6 | $193 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.